<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182779</url>
  </required_header>
  <id_info>
    <org_study_id>HIT-1</org_study_id>
    <nct_id>NCT01182779</nct_id>
  </id_info>
  <brief_title>Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base</brief_title>
  <acronym>HIT-1</acronym>
  <official_title>Randomised Trial of Proton vs. Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base -Clinical Phase III Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomised clinical phase III trial. The primary objective of
      this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is
      superior to the standard proton treatment with respect to the local-progression free survival
      (LPFS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective randomised clinical phase III trial. The trial will be carried out
      at Heidelberger Ionenstrahl-Therapie (HIT) centre as monocentric trial.

      Proton therapy is the gold standard in the treatment of skull base chordomas. However,
      high-LET beams such as carbon ions theoretically offer biologic advantages by enhanced
      biologic effectiveness in slow-growing tumors. Up until now it was impossible to compare two
      different particle therapies, i.e. proton and carbon ion therapy directly with each other.
      The aim of this study is to find out, whether the biological advantages of carbon ion therapy
      mentioned above can also be clinically confirmed.

      Patients with skull base chordoma will be randomised to either proton or carbon ion radiation
      therapy. As a standard, patients will undergo non-invasive, rigid immobilization and target
      volume delineation will be carried out based on CT and MRI data. The biologically
      isoeffective target dose to the PTV in carbon ion treatment (accelerated dose) will be 63 Gy
      E ± 5% and 72 Gy E ± 5% (standard dose) in proton therapy respectively. Local-progression
      free survival (LPFS) will be analysed as primary end point. Toxicity and survival are the
      secondary end points. Also matters of interest are patterns of recurrence, prognostic factors
      and plan quality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local-progression free survival (LPFS)</measure>
    <time_frame>8-years</time_frame>
    <description>The primary objective of this study is to evaluate, if the innovative therapy (carbon ion irradiation) in chordomas is superior to the standard proton treatment with respect to the LPFS defined as time from the randomisation to observed local reccurrence or death from any cause in the absence of documented local disease progression. Lo-cal recurrence defined as MRT or CT - morphological tumor progress in the former irradiated region. A 10% increase in the LPFS is considered clinically relevant as-suming that the LPFS rate for the proton therapy is 70%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>8-years</time_frame>
    <description>Assessment of overall survival, progression free and metastasis free survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control and patterns of recurrence</measure>
    <time_frame>8 years</time_frame>
    <description>Local recurrences will be confirmed radiologically and histologically whenever possible. At least two medical doctors (radiation oncologist and/or radiologist) will be required to judge of the recurrence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>8 years</time_frame>
    <description>Acute and late toxicity will be analysed due to Common Terminology Criteria for Adverse Events: CTCAE V4.0 for acute reaction and RTOG/EORTC for late effects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">319</enrollment>
  <condition>Chordoma</condition>
  <condition>Tumor</condition>
  <condition>Treatment</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon ion</intervention_name>
    <description>Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Protons</intervention_name>
    <description>Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Karnofsky Performance Score ≥60%

          -  Age &gt;18 years and &lt;80 years

          -  Informed consent signed by the patient

          -  Histological confirmation of chordoma with infiltration of the skull base.

        Exclusion Criteria:

          -  Inability to understand the aims of the study, no informed consent

          -  Prior RT of skull base region

          -  Other malignancies with disease-free interval &lt; 5 years (excepting pre- cancerous
             lesions)

          -  Participation in another trial

          -  Pregnancy

          -  Simultaneous CHT or Immunotherapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Debus, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna V. Nikoghosyan, MD</last_name>
    <phone>+496221568202</phone>
    <email>anna.nikoghosyan@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juergen Debus, MD, PhD</last_name>
    <phone>+496221568202</phone>
    <email>juergen.debus@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juergen Debus, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna V. Nikoghosyan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base. Strahlenther Onkol. 1999 Jun;175 Suppl 2:57-63. Review.</citation>
    <PMID>10394399</PMID>
  </reference>
  <reference>
    <citation>Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, Goitein G. Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1111-8. doi: 10.1016/j.ijrobp.2008.12.055. Epub 2009 Apr 20.</citation>
    <PMID>19386442</PMID>
  </reference>
  <reference>
    <citation>Hug EB. Review of skull base chordomas: prognostic factors and long-term results of proton-beam radiotherapy. Neurosurg Focus. 2001 Mar 15;10(3):E11. Review.</citation>
    <PMID>16734403</PMID>
  </reference>
  <reference>
    <citation>Hug EB, Slater JD. Proton radiation therapy for chordomas and chondrosarcomas of the skull base. Neurosurg Clin N Am. 2000 Oct;11(4):627-38. Review.</citation>
    <PMID>11082173</PMID>
  </reference>
  <reference>
    <citation>Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, Lomax AJ, Goitein G. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):401-9.</citation>
    <PMID>16168833</PMID>
  </reference>
  <reference>
    <citation>Schulz-Ertner D, Karger CP, Feuerhake A, Nikoghosyan A, Combs SE, Jäkel O, Edler L, Scholz M, Debus J. Effectiveness of carbon ion radiotherapy in the treatment of skull-base chordomas. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57. Epub 2007 Mar 23.</citation>
    <PMID>17363188</PMID>
  </reference>
  <reference>
    <citation>Mizoe JE, Hasegawa A, Takagi R, Bessho H, Onda T, Tsujii H. Carbon ion radiotherapy for skull base chordoma. Skull Base. 2009 May;19(3):219-24. doi: 10.1055/s-0028-1114295.</citation>
    <PMID>19881902</PMID>
  </reference>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>August 16, 2010</last_update_submitted>
  <last_update_submitted_qc>August 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Juergen Debus, MD PhD, Dept. of Radiation Oncology, INF 400, 69120 Heidelberg</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>base of skull chordoma</keyword>
  <keyword>radiation</keyword>
  <keyword>carbon ions</keyword>
  <keyword>protons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chordoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

